Drugs / BCG Moreau RJ
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03982797 | May 2019 → Apr 2021 | urinary bladder cancer | Biofabri, S.L | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG Moreau RJ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03982797 ↗ |
| Known as | IMUNO BCG Moreau RJ | “Each patient will be instillated via transurethral each time with 80 mg of IMUNO BCG Moreau RJ.” NCT03982797 ↗ |